AVIR (Atea Pharmaceuticals) Net Income Including Noncontrolling Interests: $-169.52 Mil (TTM As of Mar. 2026)


AVIR Atea Pharmaceuticals Inc AVIR
24 GF Score
Price $4.52
! 3 Warning Signs
View Full Analysis

What is Atea Pharmaceuticals Net Income Including Noncontrolling Interests?

Atea Pharmaceuticals AVIR +1.12% 24 Net Income Including Noncontrolling Interests is $-169.52 Mil as of Mar. 2026. GuruFocus rates AVIR with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Atea Pharmaceuticals's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2026 was $-45.44 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 was $-169.52 Mil.

Atea Pharmaceuticals Net Income Including Noncontrolling Interests Related Terms

Atea Pharmaceuticals Net Income Including Noncontrolling Interests Historical Data

* Premium members only.

The historical data trend for Atea Pharmaceuticals's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atea Pharmaceuticals Net Income Including Noncontrolling Interests Chart

Atea Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial 121.19 -115.91 -135.96 -168.39 -158.35

Atea Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34.27 -37.16 -42.05 -44.87 -45.44
AVIR
24GF Score
Atea Pharmaceuticals Inc AVIR
Net Income Including Noncontrolling Interests is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atea Pharmaceuticals Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-169.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income Including Noncontrolling Interests of $-169.52 Mil mean?
Atea Pharmaceuticals (AVIR) has a Net Income Including Noncontrolling Interests of $-169.52 Mil as of Mar. 2026.
Is Atea Pharmaceuticals' Net Income Including Noncontrolling Interests too high?
Atea Pharmaceuticals' current Net Income Including Noncontrolling Interests is $-169.52 Mil. Overall, Atea Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Atea Pharmaceuticals' Net Income Including Noncontrolling Interests compare to IMRX and PROK?
Atea Pharmaceuticals' Net Income Including Noncontrolling Interests of $-169.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income Including Noncontrolling Interests for a Biotechnology company?
A good Net Income Including Noncontrolling Interests depends on the Biotechnology industry context. However, Net Income Including Noncontrolling Interests should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income Including Noncontrolling Interests mean?
A high Net Income Including Noncontrolling Interests can signal that a stock is expensive relative to its fundamentals. Atea Pharmaceuticals's current Net Income Including Noncontrolling Interests is $-169.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atea Pharmaceuticals stock overvalued right now?
Atea Pharmaceuticals (AVIR) has a current Net Income Including Noncontrolling Interests of $-169.52 Mil. The current Net Income Including Noncontrolling Interests is $-169.52 Mil. Atea Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income Including Noncontrolling Interests calculated?
Net Income Including Noncontrolling Interests is calculated from a company's financial statements. For Atea Pharmaceuticals (AVIR), the current Net Income Including Noncontrolling Interests is $-169.52 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atea Pharmaceuticals Business Description

Address 225 Franklin Street, Suite 2100, Boston, MA, USA, 02110
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
24GF Score

Get the complete analysis for AVIR

Net Income Including Noncontrolling Interests is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.52
Price